Latest News for Livento Group Stock (OTC:NUGN)

Livento Group Inc is a USA-based company focused on disruptive business models. Its main area of business is the production of premium film and television content for international audiences across multiple genres under the new brand BOXO Productions. The company also develops proprietary artificial intelligence (AI) & machine learning products that incorporate risk analysis, predictive maintenance, and operational forecasting into the decision-making process. It currently occupies space within serviced office suites in New York City and Prague in the Czech Republic.

Meet The Company Finding Novel Applications For The Revolutionary Power Of AI

Movers & Shakers

Interview

General

NUGN

Sign up for this week’s All Access giveaway here! 

David Stybr, CEO of Livento Group, Inc. (OTCMKTS: NUGN), was a guest on Benzinga’s All Access on September 30, 2022.

News

Intraday Update

Markets

Movers

Trading Ideas

ABCE

AGTK

AKRX

ASKE

ATIF

AVMR

AWAW

BEMG

BIGG

BIOIF

BLEVF

BROG

BWVI

CGNH

CGOTF

CIRX

CNBX

DFODQ

DNAG

DTHR

EWLL

FABU

FDMF

FNRC

GBHPF

GGAZF

GXXM

HESG

HIHO

HMPQ

INCT

INOH

IORG

IPICQ

JUVF

KOIOS BEVERAGE CORP by Koios Beverage Corp.

KBEVF

KONAQ

LIXT

LLIT

LOGL

LPKGF

MACK

MALDF

MARA

MEIL

MGAWY

MICWF

MINE

MIST

MITO

MLNT

MNOV

MODERN CINEMA GROUP INC by Modern Cinema Group, Inc.

MOCI

MRMD

MTVX

MYBUF

NAUH

NLBIF

NSANF

NSUPF

ORHB

PHVAF

PMDP

PVSP

RCON

REGRF

RETC

RIGH

RIOT

RMTD

SIML

SLROF

SMME

SOPV

SPRT

SPVNF

SRTS

TCHC

TCRRF

TLKGY

TLRY

TPT GLOBAL TECH INC by TPT Global Tech, Inc.

TPTW

TRAC

UBQU

UNIR

VBIX

VERI

VLLX

VNET

VPRB

VSYM

WKULF

WLSI

ZCOM

ZLPSF

ZNGYQ

HKVTY

Stocks That Hit 52-Week Lows On Friday

NUGENE INTERNATIONAL, INC by NuGene International, Inc.

Livento Group Inc

Wells Fargo analyst Jason Haas maintains UL Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULS#NYSE">ULS</a>) with a Overweight and raises the price target from $40 to $43.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on UL Solutions, Raises Price Target to $43

Wells Fargo analyst Phil Winslow maintains Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) with a Underweight and lowers the price target from $70 to $60.

Wells Fargo Maintains Underweight on Zoom Video Comms, Lowers Price Target to $60

Shares of Norwegian Cruise Line Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) jumped over 7% on Monday after the company hosted its &#8220;Charting the Course&#8221; investor event. Amid management&#8217;s upward revision of 2024 Adjusted EPS from $1.32 to $1.42, two analysts shared their takeaways of Norwegian&#8217;s ability to outperform <a href="https://www.benzinga.com/topic/wall-street">Wall Street expectations</a>.
The Norwegian Cruise Analysts:
<ul>
<li>Stifel analyst Steven M. Wieczynski reiterated his Buy rating on Norwegian, raising his price target from $25 to $26.</li>
<li>Goldman Sachs analyst Lizzie Dove maintained her Neutral rating on Norwegian and raised the price target from $19 to $21.</li>
</ul>
Stifel Analyst on Norwegian Cruise: Wieczynski insisted that Norwegian management&#8217;s guidance could still be conservative, particularly in the long term with cost savings. Norwegian&#8217;s 2026 EPS guidance is approximately $2.45.
&#8220;Bottom line is we think they are super-conservative and honestly we believe their 2026 adjusted EPS could be well above $3/share,&#8221; Wieczynski said. &#8220;Now a lot goes into that statement, but if the consumer stays somewhat healthy for the foreseeable future, we don't see a reason why these long-term targets won't be met and exceeded, very similar to long-range targets that Royal Caribbean Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) (RCL/Buy) has laid out in the past.&#8221;
Wieczynski also emphasized the ongoing strength of Norwegian&#8217;s fundamental operations as a reason to be optimistic.
&#8220;Revised 2024 guidance seems pretty fair to us, but we sense the market is going to speculate if this is as good as it gets for the company. In short, we would say absolutely not. Let's try and keep this simple. Bookings remain strong. Pricing remains strong. Onboard metrics remain strong. There is no slowdown in booking activity through early-2025,&#8221; said the analyst.
Goldman Analyst on Norwegian Cruise: Dove was less optimistic about Norwegian&#8217;s ability to outperform guidance in 2024, citing &#8220;geopolitical headwinds&#8221; in the short term. However, the analyst stated that the company will still experience future growth.
&#8220;NCLH's confidence on pricing, long-term LSD-MSD net yield growth and cruise category expansion further corroborates our view that 2024 is not "peak cruise" and there are several industry pricing/demand tailwinds still to come,&#8221; said Dove.
The analyst estimated a 2026 Adj EPS of $2.45, in line with management estimates. Dove also commented on potential cost savings.
&#8220;While we were encouraged by the cost savings plan, we would have liked a little more detail on the cadence and quantity of these savings, which leaves us a little below NCLH's long term EBITDA margin guidance pending further proof points and execution,&#8221; Dove said.
NCLH Price Action: NCLH traded at $16.97, up 0.18% on the day at the time of publication.
Also Read: <a href="https://www.benzinga.com/markets/asia/24/05/38941394/goldman-sachs-raises-forecast-for-chinese-market-stock-ideas-to-bet-on-recovery-momentum">Goldman Sachs Raises Forecast For Chinese Market: Stock Ideas To Bet On Recovery Momentum</a>
Photo: Shutterstock

Entertainment

Equities

Guidance

Travel

NCLH

Turnaround Imminent For Norwegian Cruises? 2 Analysts Share Takeaways From Investor Event

WIIM

WISA

WiSA Technologies shares are trading lower after the company reported a year-over-year decrease in Q1 sales results.

U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones index gaining around 0.1% on Tuesday.
The Dow traded up 0.07% to 39,835.87 while the NASDAQ rose 0.06% to 16,805.01. The S&amp;P 500 also rose, gaining, 0.12% to 5,314.54&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/38937412/these-3-consumer-stocks-with-over-3-dividend-yields-are-recommended-by-wall-streets-most">These 3 Consumer Stocks With Over 3% Dividend Yields Are Recommended By Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Utilities shares rose by 0.6% on Tuesday.
In trading on Tuesday, industrials shares fell by 0.3%.
Top Headline
Macy's Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) reported better-than-expected first-quarter adjusted earnings and raised the outlook.
The company reported a first-quarter FY24 sales decline of 2.7% year-on-year to $4.846 billion, slightly missing the analyst consensus of $4.86 billion. Adjusted EPS of 27 cents beat the analyst consensus of 15 cents.
Macy's updated FY24 sales outlook from $22.2 billion – $22.9 billion to $22.3 billion – $22.9 billion, against the consensus of $22.81 billion. The company raised FY24 adjusted EPS guidance from $2.45 – $2.85 to $2.55 – $2.90 versus the Street view of $2.62.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>MGO Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) shares shot up 342% to $1.0101 after the company posted first-quarter results.</li>
<li>Shares of Biodexa Pharmaceuticals Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) got a boost, surging 73% to $2.2001. The company on Tuesday announced progress towards the treatment of Familial Adenomatous Polyposis.</li>
<li>Mangoceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRX#NASDAQ">MGRX</a>) shares were also up, gaining 164% to $0.6754 after the company announced the development of oral formulations of Semaglutide and Tirzepatide.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares dropped 63% to $0.0579 after the company reported a year-over-year decrease in first-quarter financial results. Also, the company announced a registered direct offering.</li>
<li>Shares of American Oncology Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) were down 33% to $1.86. American Oncology Network announced voluntary delisting from the Nasdaq.</li>
<li>LuxUrban Hotels Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) was down, falling 42% to $0.2601 after the company announced the pricing of its public offering of 30.50 million common shares at $0.25 per share.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/38937803/top-5-defensive-stocks-that-may-keep-you-up-at-night-in-q2">Top 5 Defensive Stocks That May Keep You Up At Night In Q2</a>
Commodities In commodity news, oil traded down 0.8% to $79.20 while gold traded down 0.6% at $2,424.80.
Silver traded down 0.9% to $32.12 on Tuesday, while copper rose 0.8% to $5.1175.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.18%, Germany's DAX fell 0.22% and France's CAC 40 dipped 0.66%. Spain's IBEX 35 Index fell 0.04%, while London's FTSE 100 fell 0.09%.
The Eurozone recorded a trade surplus of €24.1 billion in March compared to a €19.1 billion surplus in the year-ago month. The current account surplus in the Eurozone rose to €44.5 billion in March from €27.0 billion in the year-ago period. Construction output in the Eurozone rose 0.1% year-over-year in March.
Producer prices in Germany fell by 3.3% year-over-year in April compared to a 2.9% decline in the prior month.
Asia Pacific Markets
Asian markets closed lower on Tuesday, with Japan's Nikkei falling 0.31%, China's Composite Index declining 0.42%, Hong Kong's Hang Seng Index dipping 2.12% and India's S&amp;P BSE Sensex falling 0.1%.
Economics
No major economic reports will be released today.
Now Read This: Ho<a href="https://www.benzinga.com/news/earnings/24/05/38937789/how-to-earn-500-a-month-from-williams-sonoma-stock-ahead-of-q1-earnings">w To Earn $500 A Month From Williams-Sonoma Stock Ahead Of Q1 Earnings</a>

Earnings

Eurozone

Commodities

AONC

BDRX

GWAV

LUXH

MGOL

MGRX

Gold Moves Lower; Macy's Boosts 2024 Forecast

Mog (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">MOG</a>), a cat-themed meme coin on Ethereum, spiked 46% on Tuesday, with a trader registering a multi-<a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38843588/millionaire-trader-up-7-figures-in-48-hours-on-gamestop-and-amc-meme-coins-on-solana">million dollar unrealized profit</a>.
What Happened: The trader, operating under the Ethereum address &#8220;mogillionaire.eth,&#8221; spent 8.8 ETH (around $16,000 at the time) to acquire 3.37 trillion MOG on July 24, 2023, Lookonchain reported. 
Demonstrating confidence in his investment, he also registered the domain name "mogillionaire.eth" with dreams of millionaire status.
By Feb. 27, 2024, the 3.37 trillion MOG Coins had spiked to their all-time high value of more than $4 million. At current prices, the holdings are valued around $2.8 million.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38942883/pepe-hits-all-time-high-on-35-daily-explosion-gearing-up-for-a-2021-doge-pump-trader-write">PEPE Hits All-Time High On 35% Daily Explosion: &#8216;Gearing Up For A 2021 DOGE Pump,&#8217; Trader Writes</a>
Why It Matters: Since its launch in July 2023, Mog has risen to a valuation of $353 million. Aevo, the first Derivatives L2 focused on options &amp; perps trading, on Tuesday <a href="https://x.com/aevoxyz/status/1792948841718923647">announced</a> the listing of MOG for trading.
This trader's story highlights the volatile yet potentially lucrative nature of the crypto market, where strategic investments and a bit of luck can lead to substantial financial gain. The rise of "mogillionaire.eth" from a $16,000 investment to a millionaire status underscores the potential exponential gains of meme coins. 
Brian Garrett, founder of Future Star, noted the similarity between Pepe's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) past month&#8217;s chart to MOG's current chart.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The trend of the <a href="https://twitter.com/search?q=%24MOG&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$MOG</a> chart over the course of the past month is extremely similar to that of <a href="https://twitter.com/search?q=%24PEPE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$PEPE</a> right now <a href="https://twitter.com/search?q=%24PEPE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$PEPE</a> has a $5 Billion market cap and <a href="https://twitter.com/search?q=%24MOG&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$MOG</a> is $350 Million I don&#39;t see any reason why <a href="https://twitter.com/search?q=%24MOG&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$MOG</a> can&#39;t and/or won&#39;t be in the billions soon as well &#x1f4c8; <a href="https://t.co/nQkuZAkFFv">pic.twitter.com/nQkuZAkFFv</a>
&mdash; Brian Garrett (@BrianGarrett) <a href="https://twitter.com/BrianGarrett/status/1792908949588525288?ref_src=twsrc%5Etfw">May 21, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
What&#8217;s Next: The influence of meme coins <a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a> is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38810829/trader-nets-a-553x-return-with-meme-coin-of-the-most-memeable-cat-on-the-internet">Trader Nets A 553X Return With Meme Coin Of &#8216;The Most Memeable Cat On The Internet&#8217;</a>
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$MOG

$PEPE

Trader Turns $16K Into $2.8 Million In 10 Months With A Cat-Themed Meme Coin On Ethereum

Wells Fargo analyst Michael Blum maintains Western Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WES#NYSE">WES</a>) with a Equal-Weight and raises the price target from $34 to $35.

Wells Fargo Maintains Equal-Weight on Western Midstream, Raises Price Target to $35

Argus Research&nbsp;has upgraded&nbsp;Zimmer Biomet Holdings Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) on launching new products and tuck-in M&amp;A to build future growth drivers.&nbsp;
One such driver is the ROSA system, which&nbsp;assists in robotic surgeries to implant replacement knee, hip, and shoulder joints.&nbsp;ROSA&nbsp;is also&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/n37257931/zimmer-biomet-receives-fda-clearance-for-rosa-shoulder-system-the-worlds-first-robotic-assistant-f" rel="noreferrer noopener">used&nbsp;in neurosurgery</a>.&nbsp;
Another recent product launch is the cementless knee implant, which allows for shorter procedure times and helps to improve hospital staffing efficiency.&nbsp;
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/05/38593220/whats-going-on-with-zimmer-biomet-shares-after-q1-earnings" rel="noreferrer noopener">What&#8217;s Going On With Zimmer Biomet Shares After Q1 Earnings?</a>
The analyst notes that Zimmer plans to introduce more than 40 new products over the next 24 to 36 months. Zimmer Biomet has a tailwind from favorable population demographics and a post-pandemic recovery in elective procedure volume.&nbsp;
The analyst upgrades from Hold to Buy with a&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/ZBH/analyst-ratings" rel="noreferrer noopener">price target of $150</a>.
Argus writes that Zimmer Biomet trades at 14.1 times its 2025 EPS estimate, below the average multiple of 21.2 for its coverage universe of MedTech stocks.&nbsp;
&#8220;We believe this is an attractive valuation for Zimmer-Biomet. We like the strategy of growing EPS faster than revenue and free cash flow faster than EPS,&#8221; the analyst writes.
The analyst notes that the company admitted that its previous focus on maintaining strong gross and operating margins led to under-investment in product development.&nbsp;However, introducing new and innovative products will drive higher pricing, enhance margins, and stimulate revenue growth in the long run, Argus writes.
Price Action: ZBH shares are up 0.10% at $119.17 at last check Tuesday.
Photo via Wikimedia Commons

Analyst Color

Large Cap

Upgrades

Health Care

Orthopedic Implants Maker Zimmer Biomet Gains Analyst Upgrade Amid Promising Growth From New Products, Demographic Trends

Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) has unveiled a new version of its Copilot assistant, designed to enhance team collaboration.&nbsp;
The move is part of the company's broader strategy to integrate artificial intelligence across its product line.
This AI assistant&nbsp;is Named&nbsp;Team Copilot&nbsp;and&nbsp;is designed to facilitate meetings by taking notes, summarizing key points, and managing deadlines.&nbsp;
The&nbsp;service will become available to corporate clients later this year, Microsoft stated at its annual Build conference for developers,&nbsp;<a target="_blank" href="https://www.bloomberg.com/news/articles/2024-05-21/microsoft-introduces-copilot-assistant-to-help-teams-collaborate?srnd=technology-vp&amp;sref=TBDibEcD" rel="noreferrer noopener">Bloomberg</a>&nbsp;writes.
Microsoft has positioned itself as a frontrunner in the generative AI sector, investing around $13 billion in&nbsp;OpenAI, the creator of ChatGPT.&nbsp;
This investment has led to the incorporation of advanced AI capabilities into Microsoft's productivity tools under the Copilot brand, which includes a coding assistant and an AI-enhanced search engine in Windows.
During the conference, Microsoft also revealed progress in developing its&nbsp;own&nbsp;chips. The&nbsp;Azure Cobalt 100&nbsp;CPU, the company's first proprietary processor, is now available in preview for Azure cloud service users.&nbsp;
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/05/38931937/microsoft-touts-ai-capable-surface-notebooks-58-faster-than-m3-macbook-air-we-have-essentially-the-b" rel="noreferrer noopener">Microsoft Touts AI-Capable Surface Notebooks 58% Faster Than M3 MacBook Air: ‘We Have Essentially The Best Specs,' Says Satya Nadella</a>
Although not designed for high-end AI tasks, the Cobalt chip signifies a&nbsp;huge&nbsp;step in Microsoft's strategy to compete with leading cloud providers by offering&nbsp;custom-built devices at lower costs.
Both&nbsp;Amazon.com Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and&nbsp;Alphabet Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) have been developing their&nbsp;own&nbsp;chips, enabling them to provide cost-effective solutions compared to traditional chipmakers like&nbsp;Intel Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and&nbsp;Advanced Micro Devices Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>).&nbsp;
Last week, the tech giant said its Azure cloud service will integrate AMD's MI300X AI chips,&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/05/38890649/microsoft-unveils-amd-powered-ai-chips-to-rival-nvidia-report" rel="noreferrer noopener">offering an alternative</a>&nbsp;to&nbsp;Nvidia Corp's&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) high-demand H100 GPUs.&nbsp;
Microsoft's entry into this space&nbsp;is aimed&nbsp;at enhancing&nbsp;its cloud computing services and&nbsp;reducing&nbsp;reliance on third-party hardware.
Microsoft stock has gained more than 33% in the past 12 months. Investors can gain exposure to the stock via&nbsp;the Technology&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)&nbsp;and&nbsp;IShares U.S. Technology ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYW#NYSE">IYW</a>).&nbsp;
Price Action: MSFT shares are trading higher by 1.18% at $430.34 at the last check Tuesday.
Disclaimer:&nbsp;This content was partially produced&nbsp;with the help of&nbsp;AI tools and&nbsp;was&nbsp;reviewed and published by Benzinga editors.
Read Next: <a href="https://www.benzinga.com/markets/equities/24/05/38651075/microsoft-takes-on-google-and-openai-with-new-ai-model-report" target="_blank" rel="noreferrer noopener">Microsoft Takes On Google And OpenAI With New AI Model: Report</a>
Image via Microsoft

Tech

AMZN

GOOGL

INTC

iShares Dow Jones US Technology Sector Index Fund

MSFT

NVDA

Microsoft Launches Team Copilot To Boost Workplace Collaboration

On May 17, 2024, SCWorx Corp. (the "Company") received a further notice (the "Notice") from The Nasdaq Stock Market, LLC ("Nasdaq") indicating that, as a result of not having timely filed its Form 10-Q for the period ended March 31, 2024, and because it remains delinquent in filing its Form 10-K for the year ended December 31, 2023, the Company has failed to satisfy a standard for continued listing, namely &nbsp;Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic reports with the SEC.

WORX

SCWorx Receives Notice From NASDAQ As A Result Of Not Filing Its Form 10-Q For The Period Ended March 31, 2024 Timely; Remains Delinquent In Filing Its Form 10-K For The Year Ended December 31, 2023

On Monday,&nbsp;Larimar Therapeutics&nbsp;Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) announced that the FDA removed the previous&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/21/05/21292255/larimar-stock-craters-after-fda-clinical-hold-on-friedreichs-ataxia-program" rel="noreferrer noopener">partial clinical hold</a>&nbsp;on&nbsp;-nomlabofusp&nbsp;(CTI-1601) clinical program for Friedreich&#8217;s Ataxia (FA).&nbsp;
Nomlabofusp is a novel protein replacement therapy designed to address the root cause of FA by delivering&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/g38926252/larimar-therapeutics-announces-fda-has-removed-partial-clinical-hold-for-nomlabofusp-program-in-fr" rel="noreferrer noopener">frataxin to mitochondria</a>.&nbsp;
The FDA removed the partial clinical hold&nbsp;after reviewing data from the company&#8217;s recently completed&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/02/37072080/why-is-inherited-rare-disease-focused-larimar-therapeutics-stock-trading-lower-today" rel="noreferrer noopener">Phase 2 dose exploration study</a>.&nbsp;
The review included data from the 25 mg and 50 mg cohorts in patients who received daily dosing of&nbsp;nomlabofusp&nbsp;for 14 days, followed by every other day&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/22/09/28865202/after-one-year-of-regulatory-hold-larimars-ataxia-candidate-sees-some-hope" rel="noreferrer noopener">dosing until day 28</a>.
In the Phase 2 dose exploration study,&nbsp;nomlabofusp&nbsp;was&nbsp;generally&nbsp;well-tolerated throughout the four-week treatment period.&nbsp;
Nomlabofusp had a predictable pharmacokinetic profile and demonstrated dose-dependent increases in frataxin levels in skin and buccal cells.&nbsp;
All patients with quantifiable levels at baseline and Day 14 in the 50 mg cohort achieved frataxin levels in skin cells over 33% of the average level observed in healthy volunteers&nbsp;at&nbsp;Day 14, and 3 patients achieved levels greater than 50% of the average healthy volunteer level.
The long-term safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues following&nbsp;nomlabofusp&nbsp;are currently&nbsp;being evaluated&nbsp;in the ongoing OLE study.
The OLE study will initially evaluate daily subcutaneous injections of 25 mg of&nbsp;nomlabofusp.
Larimar plans to&nbsp;dose&nbsp;escalate&nbsp;to 50 mg in the OLE study following additional characterization of frataxin PD at the 25 mg dose.&nbsp;
William Blair&nbsp;writes that the 50 mg dose can potentially increase FXN levels beyond the 5%-10% increase over baseline KOLs have suggested as a therapeutic threshold.
If necessary, dose escalation above 50 mg would require the submission of additional data for FDA review to support the increased dose.&nbsp;
Interim data from the OLE study&nbsp;is expected&nbsp;in the fourth quarter of 2024.
The analyst sees&nbsp;nomlabofusp&nbsp;as the leading therapy to boost FXN expression, which is differentiated from&nbsp;Biogen Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) Skyclarys and could&nbsp;potentially&nbsp;be used&nbsp;adjunctively&nbsp;pending&nbsp;safety data. William Blair reiterates the&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/LRMR/analyst-ratings" rel="noreferrer noopener">Outperform rating on Larimar</a>.
Price Action: LRMR shares are up 10.66% at $8.05 at last check Tuesday.
Photo via Shutterstock

Biotech

Reiteration

BIIB

Larimar Therapeutics, Inc. - Common Stock

LRMR

Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed Drug

PRST

Presto Automation shares are trading higher after the company reported better-than-expected Q3 sales results.

Lawyer and activist Robert F. Kennedy Jr. announced via his X account the purchase of GameStop Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares Tuesday, joining the meme stock movement by retail traders that gained steam in 2021 and was renewed with a <a href="https://www.benzinga.com/general/education/24/05/38793704/who-is-roaring-kitty-why-does-his-return-to-social-media-matter-for-gamestop-stock">return of Roaring Kitty on social media.</a>
What Happened: Meme stocks like GameStop and AMC Entertainment Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) saw a surge in interest and volatility last week after Roaring Kitty, aka Keith Gill, made <a href="https://www.benzinga.com/markets/equities/24/05/38787490/gamestop-shares-surge-as-roaring-kitty-resurfaces-after-3-year-silence">a return to social media platform X.</a>
On Tuesday, the <a href="https://www.benzinga.com/markets/cryptocurrency/23/10/35152268/robert-f-kennedy-jr-launches-third-party-bid-draws-ire-of-siblings-republican-party-a-demo">2024 presidential candidate</a> posted that he bought $24,000 in GameStop shares to support the movement.
"I'm very aware of what the average retail investors has been saying about the need for greater transparency in our markets, stronger regulatory oversight and tougher penalties for market manipulation and criminal behavior," Kennedy <a href="https://x.com/RobertKennedyJr/status/1792970117204287992">tweeted</a>. Benzinga reached out to Kennedy Jr.'s campaign team on the validity of the tweet and has not heard back as of the time of publication.
The tweet showed a picture of Kennedy running for office in the 2024 election with the caption "Apes Together Strong" resembling a movie poster.
"My administration will support the Ape retail rebellion and enact aggressive Wall Street reforms. To match action with words, I just invested $24,000 in GameStop from the fees I earned from suing Monsanto for their knowingly poisoning our soil and causing cancer."
Kennedy said we need to make a "free and fair market" and he loves the thought of making Monsanto support GameStop and the Apes.
"Let's punish predatory short selling to the moon. By the way, I ride with you and I'm not leaving."
The tweet from Kennedy tagged several X accounts including Roaring Kitty and also included hashtags for ApesNotLeaving, ApesTogetherStrong GME and AMC.
Kennedy&#8217;s tweet was made around an hour after posting about wanting to be included in 2024 election debates with Donald Trump and Joe Biden.
Related Link: <a href="https://www.benzinga.com/general/social-media/24/05/38828268/robert-f-kennedy-sues-meta-platforms-ceo-mark-zuckerberg-accuses-social-media-giant-of-suppr">Robert F. Kennedy Sues Meta Platforms, CEO Mark Zuckerberg, Accuses Social Media Giant Of Suppressing Third-Party White House Campaign</a>
Why It's Important: A push to <a href="https://www.benzinga.com/topic/congress-trading">ban members of Congress</a> from buying and selling stocks and options continues to gain steam, with potential red flags over trades.
Presidents and presidential candidates often don't hold individual stock positions. The position from Kennedy could represent one of the biggest validations of the meme stock movement by a politician.
<a href="https://www.benzinga.com/general/politics/24/05/38872607/lawmakers-massively-missed-out-on-meme-stocks-1-lucky-elected-official-traded-both-gamestop-amc">Data tracked by Benzinga </a>showed only one member of Congress traded GameStop and AMC stock over the last two years.
Kennedy is a cryptocurrency supporter and <a href="https://www.benzinga.com/markets/cryptocurrency/23/07/33409075/robert-kennedy-jr-bought-14-bitcoin-worth-400k-for-his-kids-no-one-can-say-i-didnt-put-my-">previously shared that he had bought </a>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) for his children.
The 2024 presidential candidate could gain support from cryptocurrency investors and retail traders with his publicly announced positions.
GME Price Action: GameStop shares are down 9% to $20.96 on Tuesday, versus a 52-week trading range of $9.95 to $64.83. GameStop stock is down 13.4% over the last year and up 19.6% year-to-date in 2024.
Read Next: <a href="https://www.benzinga.com/top-stories/24/05/38945975/meme-stocks-gamestop-amc-fade-in-interest-after-roaring-kitty-exit-heres-what-wallstreetbets-is-eyei">Meme Stocks GameStop, AMC Fade In Interest After Roaring Kitty Exit: Here&#8217;s What WallStreetBets Is Eyeing Next</a>
Photo: Shutterstock

Politics

$BTC

RFK Jr. Announces GameStop Stock Purchase On X Account: 'My Administration Will Support The Ape Retail Rebellion'

OLB Group shares are trading lower after the company reported a year-over-year decrease in its Q1 sales results.

Tuesday, the&nbsp;FDA's&nbsp;staff reviewers raised concerns regarding&nbsp;Guardant Health&nbsp;Inc's&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) experimental blood test for colorectal cancer, suggesting it might not detect some tumor types that could become cancerous.&nbsp;
Guardant Health is seeking approval&nbsp;for&nbsp;Shield, a blood-based colorectal cancer (CRC) screening test for average-risk adults.&nbsp;
Shield is an in vitro diagnostic device intended for&nbsp;the qualitative detection of&nbsp;CRC through sequencing the cell-free DNA (cfDNA) isolated from whole blood.
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37291016/cancer-test-focused-guardant-health-stock-falls-on-fda-adcom-update-for-colorectal-" rel="noreferrer noopener">Cancer Test Focused Guardant Health Stock Falls On FDA AdCom Update For Colorectal Test</a>.
The FDA document noted,&nbsp;"Patients with advanced neoplasia (AA) have a high risk of developing CRC cancer. The Guardant ECLIPSE study demonstrated 83.1% sensitivity for CRC but only 13.2% sensitivity for the detection of AA."
The&nbsp;FDA's&nbsp;Molecular and Clinical Genetics Panel&nbsp;is&nbsp;<a target="_blank" href="https://www.businesswire.com/news/home/20240421042636/en/FDA-Advisory-Panel-Review-of-Guardant-Health%E2%80%99s-Shield%E2%84%A2-Blood-Test-to-Screen-for-Colorectal-Cancer-to-Be-Held-on-May-23" rel="noreferrer noopener">scheduled</a>&nbsp;to meet on Thursday, 23 May, to review the premarket approval application for the&nbsp;company's&nbsp;Shield blood test for colorectal cancer screening.
Despite this, the reviewers acknowledged the&nbsp;test's&nbsp;potential benefits, noting that it could improve compliance with colorectal cancer screenings and aid in early detection, potentially curing patients and extending survival rates.
If approved,&nbsp;Guardant's&nbsp;Shield test could become the second blood-based colorectal cancer test available in the United States.
Colorectal cancer affects approximately 150,000 people in the U.S. annually and is the second-leading cause of cancer deaths in the country, claiming over 50,000 lives each year.&nbsp;
The screening market for colorectal cancer in the U.S.&nbsp;is valued&nbsp;at nearly $20 billion.&nbsp;
Despite advancements,&nbsp;about 60 million people, or 50%, remain unscreened, Reuters noted, citing&nbsp;TD Cowen&nbsp;analyst.
The&nbsp;U.S. Centers for Medicare and Medicaid Services (CMS)&nbsp;has stated it would reimburse blood-based biomarker colorectal cancer tests that show a minimum sensitivity of 74%, pending FDA approval.
In contrast, the first blood biomarker test for colorectal cancer,&nbsp;Epigenomics'&nbsp;Epi proColon, was approved by the FDA in 2016 but was not reimbursed by the CMS in 2021 due to its 68.2% sensitivity.&nbsp;
Epigenomics, now owned by New Day Diagnostics and rebranded as ColoHealth, highlights the competitive landscape for&nbsp;Guardant's&nbsp;Shield as it seeks approval and potential market entry.
Price Action: GH shares are down 2.62% at $24.12 at last check Tuesday.
Image by PDPics from Pixabay

Media

What's Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday?

Macro Economic Events

Economics

JBLU

SAVE

ULCC

Airlines Say It Is "Past Time" For FAA To Boost Air Traffic Controller Staffing, Calling For Urgent Hiring

American Oncology Network shares are trading lower after the company announced that it will voluntarily delist from the Nasdaq.

American Oncology Network ("AON" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>), a rapidly growing network of community-based oncology practices, announced today its decision to voluntarily delist its Class A common stock and warrants from The Nasdaq Capital Market ("Nasdaq"). The Company's decision to delist its securities from Nasdaq was recommended to the Board of Directors (the "Board") of the Company by a Special Committee (the "Special Committee") of the Board comprised solely of independent directors. &nbsp;
The Company intends to file a Form 25 with the Securities and Exchange Commission (the "SEC") to delist its Class A common stock and warrants from Nasdaq and to deregister its Class A common stock and warrants under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), on or about May 31, 2024, and as a result, the Company expects that the last trading day of its Class A common stock and warrants on Nasdaq will be on or about June 7, 2024.

American Oncology Network Earlier Reported It Will Voluntary Delist From Nasdaq; Expects That The Last Trading Day Of Its Class A Common Stock And Warrants On Nasdaq Will Be On Or About June 7, 2024.

Whales with a lot of money to spend have taken a noticeably bullish stance on Datadog.
Looking at options history for Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $106,445 and 7, calls, for a total amount of $550,491.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $110.0 and $170.0 for Datadog, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Datadog's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Datadog's substantial trades, within a strike price spectrum from $110.0 to $170.0 over the preceding 30 days.
<h3>Datadog Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1716316287_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$13.95</td>
<td>$13.15</td>
<td>$13.95</td>
<td>$110.00</td>
<td>$279.0K</td>
<td>838</td>
<td style="text-align: right;">204</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$1.89</td>
<td>$1.81</td>
<td>$1.84</td>
<td>$130.00</td>
<td>$64.4K</td>
<td>4.0K</td>
<td style="text-align: right;">366</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$3.6</td>
<td>$3.4</td>
<td>$3.41</td>
<td>$170.00</td>
<td>$51.1K</td>
<td>301</td>
<td style="text-align: right;">150</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$3.65</td>
<td>$3.55</td>
<td>$3.6</td>
<td>$125.00</td>
<td>$48.9K</td>
<td>3.6K</td>
<td style="text-align: right;">173</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$14.65</td>
<td>$14.55</td>
<td>$14.65</td>
<td>$130.00</td>
<td>$41.0K</td>
<td>2.9K</td>
<td style="text-align: right;">42</td>
</tr>
</tbody>
</table>

<h3>About Datadog</h3>
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered via software as a service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of applications throughout their businesses.
In light of the recent options history for Datadog, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Datadog</h3>
<ul>
<li>Currently trading with a volume of 1,557,089, the DDOG's price is down by -0.72%, now at $120.42. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 77 days.</li>
</ul>
<h3>Professional Analyst Ratings for Datadog</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $154.2.
<ul>
<li>In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $165. </li>
<li>An analyst from Rosenblatt persists with their Buy rating on Datadog, maintaining a target price of $146. </li>
<li>An analyst from BMO Capital persists with their Outperform rating on Datadog, maintaining a target price of $140. </li>
<li>An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $165. </li>
<li>An analyst from Wedbush has revised its rating downward to Outperform, adjusting the price target to $155. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Datadog options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

DDOG

Unpacking the Latest Options Trading Trends in Datadog

Investors with a lot of money to spend have taken a bullish stance on United States Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with X, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for United States Steel.
This isn't normal.
The overall sentiment of these big-money traders is split between 62% bullish and 37%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $278,042, and 2 are calls, for a total amount of $126,730.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $40.0 for United States Steel over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for United States Steel's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of United States Steel's whale activity within a strike price range from $30.0 to $40.0 in the last 30 days. 
<h3>United States Steel Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1716316282_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$8.85</td>
<td>$7.3</td>
<td>$8.85</td>
<td>$30.00</td>
<td>$86.7K</td>
<td>32</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$6.35</td>
<td>$6.3</td>
<td>$6.3</td>
<td>$40.00</td>
<td>$63.0K</td>
<td>119.5K</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$6.0</td>
<td>$5.7</td>
<td>$5.9</td>
<td>$40.00</td>
<td>$59.0K</td>
<td>368</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$5.0</td>
<td>$3.6</td>
<td>$5.0</td>
<td>$40.00</td>
<td>$49.5K</td>
<td>902</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$1.06</td>
<td>$0.98</td>
<td>$0.98</td>
<td>$35.00</td>
<td>$49.0K</td>
<td>3.6K</td>
<td style="text-align: right;">541</td>
</tr>
</tbody>
</table>

<h3>About United States Steel</h3>
United States Steel Corp operates primarily in the United States but also has a steelmaking capacity in Slovakia. The company's operating segments include North American Flat-Rolled (Flat-Rolled), Mini Mill, U. S. Steel Europe (USSE), and Tubular Products (Tubular). The Flat-Rolled segment includes U. S. Steel's integrated steel plants and equity investees in North America involved in the production of slabs, strip mill plates, sheets, and tin mill products, as well as all iron ore and coke production facilities in the United States. It primarily serves North American customers in the service center, conversion, transportation, construction, container, and appliance, and electrical markets.
Having examined the options trading patterns of United States Steel, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of United States Steel</h3>
<ul>
<li>With a volume of 1,116,654, the price of X is down -0.19% at $36.68. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 65 days.</li>
</ul>
<h3>Expert Opinions on United States Steel</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $45.333333333333336.
<ul>
<li>An analyst from Jefferies downgraded its action to Buy with a price target of $45. </li>
<li>An analyst from Morgan Stanley has elevated its stance to Overweight, setting a new price target at $48. </li>
<li>An analyst from JP Morgan has decided to maintain their Neutral rating on United States Steel, which currently sits at a price target of $43. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest United States Steel options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Market Whales and Their Recent Bets on United States Steel Options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Livento Group Stock (OTC:NUGN)

Wednesday, October 05, 2022

Friday, December 27, 2019